Skip to main contentAI and Advanced
/
AARTIDRUGS · NSEMarket ticker unavailable · configure an authorised index feed
AA
NSE · Equity shares · Biotechnology & Drugs-2.90 · -0.68%
Aarti Drugs AARTIDRUGS
NSE:INR 422.1
BSE:INR 411.6
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for AARTIDRUGS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 425
Day rangeINR 411 — INR 431.7
52-week rangeINR 318.95 — INR 534.55
Volume1.38 L
Market cap3,759.86
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,565.31
Net Income (INR Cr)194.92
EPS21.36
Research path: Interpret Aarti Drugs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
AARTIDRUGSAarti Drugs1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,815.26 | 2,574.68 | 2,432.36 |
| Cash Equivalents | 8.81 | 4.58 | 6.74 |
| Other Liabilities Total | 4.77 | 4.49 | 2.91 |
| Long Term Debt | 256.87 | 284 | 275.33 |
| Common Stock Total | 91.27 | 91.27 | 91.94 |
| Other Equity Total | 0.01 | 10.5 | 8.91 |
| Other Current Assets Total | 122.14 | 81.45 | 109.77 |
| Total Assets | 2,815.26 | 2,574.68 | 2,432.36 |
| Current Portof LT Debt/Capital Leases | 318.91 | 57.59 | 73.33 |
| Total Equity | 1,548.87 | 1,369 | 1,281.55 |
| Long Term Investments | 27.31 | 22.41 | 19.97 |
| Retained Earnings(Accumulated Deficit) | 1,457.59 | 1,267.23 | 1,180.71 |
| Total Common Shares Outstanding | 9.13 | 9.13 | 9.19 |
| Tangible Book Valueper Share Common Eq | 167.9 | 143.07 | 135.39 |
| Total Liabilities | 1,266.39 | 1,205.68 | 1,150.81 |
| Total Debt | 576.64 | 615.07 | 564.28 |
| Short Term Investments | 15.47 | 17 | 13.07 |
| Cashand Short Term Investments | 24.28 | 21.57 | 19.82 |
| Total Receivables Net | 830.57 | 762.41 | 705.24 |
| Deferred Income Tax | 81.27 | 78.23 | 75.71 |
| Accounts Receivable-Trade Net | 829.87 | 751.18 | 704.55 |
| Property/Plant/Equipment Total-Net | 1,283.78 | 1,133.1 | 1,035.14 |
| Minority Interest | 0.36 | 0.34 | 0.41 |
| Total Current Liabilities | 922.26 | 836.97 | 795.54 |
| Total Inventory | 490.78 | 472.93 | 485.89 |
| Accounts Payable | 477.88 | 416.14 | 425.49 |
| Other Currentliabilities Total | 125.47 | 87.12 | 79.06 |
| Total Long Term Debt | 257.73 | 285.65 | 276.24 |
| Intangibles Net | 16.43 | 63.19 | 36.82 |
| Other Long Term Assets Total | 19.97 | 0.82 | 0 |
| Total Current Assets | 1,467.77 | 1,338.36 | 1,320.72 |
| Capital Lease Obligations | 0.86 | 1.65 | 0.91 |
| Accumulated Depreciation Total | Not available | -628 | -576.67 |
| Accrued Expenses | Not available | 4.29 | 2.95 |
| Property/Plant/Equipment Total-Gross | Not available | 1,486.96 | 1,386.58 |
| Notes Payable/Short Term Debt | Not available | 271.84 | 214.7 |
| Note Receivable-Long Term | Not available | 16.8 | 19.7 |
Fundamentals
Valuation and ratios
Valuation
Price to Sale Ratio1.47
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk29.5
Analyst consensus
ConsensusHold
Consensus score3.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count1
Buy count0
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
Peer data unavailable in the company profile payload.
Shareholding
Ownership
- Promoter
- 54.43%
- FII
- 1.52%
- MF
- 10.08%
- Other
- 33.97%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
GPCB orders closure of Aarti Drugs' Saykha amines plant over environmental non-compliances - Indian Pharma PostMarket news · 19 Jul 2026, 6:30 pm
GPCB orders closure of Aarti Drugs' Saykha amines plant over environmental non-compliances Indian Pharma Post
Aarti Drugs ordered by GPCB to cease operations at Gujarat plant - Business UpturnMarket news · 18 Jul 2026, 10:49 pm
Aarti Drugs ordered by GPCB to cease operations at Gujarat plant Business Upturn
Aarti Drugs: Gujarat Pollution Control Board orders closure of Saykha Amines unit - WhalesbookMarket news · 18 Jul 2026, 10:43 pm
Aarti Drugs: Gujarat Pollution Control Board orders closure of Saykha Amines unit Whalesbook
Aarti Drugs Ltd is Rated Sell - MarketsMojoMarket news · 17 Jul 2026, 2:32 am
Aarti Drugs Ltd is Rated Sell MarketsMojo
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Market Signals - MarketsMojoMarket news · 17 Jul 2026, 2:07 am
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Market Signals MarketsMojo
Corporate actions
Events
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- dividendRs.2.0000 per share(20%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
Rusaka Markets Community
Discussion and sentiment for Aarti Drugs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Not available
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- AARTIDRUGS
- BSE Code
- 524348
Questions
Stock FAQ
What is the symbol and ISIN of Aarti Drugs?
Aarti Drugs has the symbol AARTIDRUGS and ISIN - INE767A01016.
What is the current price of Aarti Drugs?
Aarti Drugs is currently trading at INR 422.10.
What are the year high and year low of Aarti Drugs?
Aarti Drugs has a year high of INR 534.55 and a year low of INR 318.95.
What is the market capitalization of Aarti Drugs?
Aarti Drugs has a market capitalization of INR 3,759.86 crore.
What is the P/E ratio of Aarti Drugs?
Aarti Drugs has a P/E ratio of NA.
What is the dividend yield of Aarti Drugs?
Aarti Drugs has a dividend yield of NA.
How is the financial performance of Aarti Drugs based on revenue, net income, and EPS?
Aarti Drugs has revenue of INR 2,565.31 crore, net income of INR 194.92 crore, and EPS of NA.
What is the book value of Aarti Drugs?
Aarti Drugs has a book value of NA.
What is the debt-to-equity ratio of Aarti Drugs?
Aarti Drugs has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Aarti Drugs?
Aarti Drugs has a price-to-book ratio of NA and a price-to-sales ratio of 1.47.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.